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Background: Muscle diseases have been associated with changes in the expression of proteins involved in energy
metabolism. To this aim we have developed a number of monoclonal antibodies against proteins of energy
metabolism.
Methods: Herein, we have used Reverse Phase Protein Microarrays (RPMA), a high throughput technique, to
investigate quantitative changes in protein expression with the aim of identifying potential biomarkers in rare
neuromuscular diseases. A cohort of 73 muscle biopsies that included samples from patients diagnosed of
Duchenne (DMD), Becker (BMD), symptomatic forms of DMD and BMD in female carriers (Xp21 Carriers), Limb
Girdle Muscular Dystrophy Type 2C (LGMD2C), neuronal ceroid lipofuscinosis (NCL), glycogenosis type V (Mc Ardle
disease), isolated mitochondrial complex I deficiency, intensive care unit myopathy and control donors were
investigated. The nineteen proteins of energy metabolism studied included members of the mitochondrial
oxidation of pyruvate, the tricarboxylic acid cycle, β-oxidation of fatty acids, electron transport and oxidative
phosphorylation, glycogen metabolism, glycolysis and oxidative stress using highly specific antibodies.
Results: The results indicate that the phenotype of energy metabolism offers potential biomarkers that could be
implemented to refine the understanding of the biological principles of rare diseases and, eventually, the
management of these patients.
Conclusions: We suggest that some biomarkers of energy metabolism could be translated into the clinics to
contribute to the improvement of the clinical handling of patients affected by rare diseases.
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Genetic alterations that result in cellular dysfunction are
usually accompanied by changes in the expression of
proteins of energy metabolism. A good example in this
regard is provided by the chromosomal abnormalities
and multiple genetic mutations that promote cancer and
that converge in the reprogramming of energy metabol-
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article, unless otherwise stated.tool as biomarker of disease progression [3,4] and of the
eventual response to therapy [5,6]. Most rare diseases
have no cure and the living with the disease until the pa-
tient becomes diagnose, if at all, is a heavy burden for
the patient and for their families. Hence, there is an ur-
gent need to identify biomarkers that could aid in the
diagnosis and/or follow up of these patients in order to
increase the understanding of disease processes that
could be further translated into potential therapeutic
interventions.
Reverse Phase Protein Microarrays (RPMA) is a high-
throughput technique that allows the quantification of aCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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logical specimens [7,8]. The application of this technology
allows the identification of new markers of diagnosis, the
establishment of correlations between protein markers
and the severity and progression of the disease and, even-
tually, of the response to a given treatment [7,8]. However,
a bottle-neck in the application and development of
RPMA is the availability of high-affinity and specific
monoclonal antibodies that could be used in the unam-
biguous characterization of a particular phenotype, either
because the antibodies have not been developed or they
lack the required specificity [9,10]. As part of an ambitious
project aimed at translating the “signature” of energy me-
tabolism to bed-side application, we are producing specific
monoclonal antibodies against enzymes of glycolysis and
mitochondrial oxidative phosphorylation [11-13] to be
applied in RPMA or any other technique, with the aim of
facilitating patient management affected with different
pathologies [4].
In the present investigation, we have produced additional
antibodies against proteins of energy metabolism and
applied RPMA technology to quantify and study the puta-
tive relevance of nineteen of these proteins as potential
biomarkers in a cohort of seventy three muscle biopsies in-
cluding control donors and patients affected of rare neuro-
muscular diseases such as Duchenne (DMD) and Becker
(BMD) dystrophies, symptomatic forms of DMD and
BMD in female carriers (Xp21 Carriers), Limb Girdle Mus-
cular Dystrophy Type 2C (LGMD2C), neuronal ceroid
lipofuscinosis (NCL), glycogen storage disease type V (Mc
Ardle disease), isolated deficiency of mitochondrial respira-
tory chain complex I and intensive care unit myopathy.
The results obtained indicate that enzymes of energy
metabolism might offer relevant biomarkers that could aid
the understanding of the biology of rare neuromuscular
diseases and, eventually, the management of these patients.
Methods
Patients and protein extraction
A cohort of deltoid and quadriceps muscle biopsies of
control donors (n = 20) and patients affected of neuro-
muscular diseases including Duchenne (DMD, n = 6),
Becker (BMD, n = 6), symptomatic forms of DMD and
BMD in female carriers (Xp21 Carriers, n = 4), Limb
Girdle Muscular Dystrophy Type 2C (LGMD2C, n = 6),
glycogenosis type V (McArdle disease, n = 7), deficit of
mitochondrial Complex I (n = 12), neuronal ceroid
lipofuscinosis (NCL, n = 6) and intensive care unit my-
opathy (n = 6) were processed. Frozen tissue sections
obtained from surgical specimens were provided from
Instituto de Investigación Biomédica de Vigo, Vigo and
from Instituto de Investigación Hospital 12 de Octubre,
Madrid, Spain. Routine histopathological study and appro-
priate molecular and clinical diagnosis of all the casesstudied had been previously performed. The samples were
obtained with informed consent following the Declaration
of Helsinki and coded for anonymity to protect patient
confidentiality. The Institutional Review Board approved
the project. For protein extraction, the samples were ho-
mogenized in T-PER Tissue Protein Extraction Reagent
(ThermoScientific, Inc. Madrid, Spain) containing prote-
ase inhibitors (protease Cocktail Tablets; Life Sciences,
Madrid, Spain) in a 1:5 (w/v) ratio, and further freeze–
thawed three times in liquid nitrogen [4]. The protein con-
centration was determined with the Bradford reagent
(Bio-Rad, Inc. Madrid, Spain) using BSA as standard.
Cloning strategies, protein expression and purification
To obtain the recombinant proteins to be used for anti-
body production the cDNAs encoding human lactate de-
hydrogenase A (LDH-A; NP_005566), NADH-ubiquinone
oxidoreductase α-subunit 9 (NADH-sub9; NM_005002),
aconitase I (ACO1; NM_002197), glycerol-3-phosphate de-
hydrogenase 1 (GPD1; NM_005276) and citrate synthase
(CS; NM_004077) were amplified by polymerase chain re-
action as previously described [11]. The sequences of the
forward (F) and reverse (R) primers used were as follows:
LDH-A (F: 5′-GAGCTCATGGCAACTCTAAAGGATCA
GC-3′; R: 5′- GCGGCCGCAAATTGCAGCTCCTTTTG
GAT - 3′); NADH-sub9 (F: 5′-CGGGAGCTCATGGCGG
CTGCCG-3′; R: 5′-ATAGTTTAGCGGCCGCTGAATGT
TGACGGTCTTG-3′); ACO1 (F: 5′-GAGCTCATGCGTG
TCATCCTGCAGGACTTT - 3′; R: 5′ GCGGCCGCGAT
GGTTCCAGCAATTGCAT - 3′); GPD1 (F: 5′ CGGGAG
CTCATGGCTAGCAAGAAAGTCT - 3′; R: 5′- ATAGTT
TAGCGGCCGCCACATATGTTCTGGATGATT - 3′);
and CS (F: 5’ CGGAAGCTTATGGCTTTACTTACTG
CG-3’; R: 5’-ATAGTTTACACGTGACCCACCCTGAC
TTAGA-3’). Amplicons were first cloned into pGEM-T
easy vector (Promega, Madison, WI) and after into pQE-
Trisystem (for details see [11]). The resulting plasmids,
pQE-LDH-A, pQE-NADH-sub9, pQE-ACO1, pQE-GPD1
and pQE-CS were used to transform Escherichia coli M15/
pREP4 cells. It should be noted that pQE-ACO1 expresses
a truncated version of ACO1. After induction of protein ex-
pression by adding IPTG (1 mM), the cells were resus-
pended in buffer A containing 100 mM NaH2PO4,
300 mM NaCl, pH 8.0 supplemented with lysozyme 1 mg/
ml. The expressed proteins were purified using either
Strep-Tactin or metal ion affinity chromatography Ni-NTA
superflow resins (Qiagen, Hilden, Germany). The purity of
the proteins was estimated by fractionation on SDS-PAGE
(Additional file 1: Figure S1).
Antibody production
BALB/c mice were immunized by intraperitoneal injection
with various dosages of the purified proteins (20 μg).
Serum was obtained from mice and tested for reactivity
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blotting (Additional file 1: Figure S1). When a titer higher
than 1000 was attained, hybridomas were produced by
fusing spleen cells with myeloma SP2 or NS-1 cells with
polyethylene glycol in HAT-RPMI 1640 medium accord-
ing to standard hybridoma techniques [11-13]. Superna-
tants of the hybridomas were screened by indirect ELISA
on polystyrene plates coated with the recombinant pro-
teins (0–150 ng per well). Bound antibodies were detected
using horseradish peroxidase–labeled goat antimouse anti-
bodies (1:1000) (DAKO, Carpinteria, CA). After the final
washing, 100 μl of OPD solution (Sigma, St. Louis, MO)
was added, and the color reaction was developed for
15 minutes and stopped by the addition of 18 M H2SO4.
Optical density at 490 nm was determined in a FluoStar
Optima (BMG Labtech, Offenburg, Germany) apparatus.
The positive colonies were cloned by limiting dilution.
Mouse monoclonal antibodies were purified with Montage
antibody purification kit (Millipore, Billerica, MA) ac-
cording to the supplier’s instructions. Highly specific
monoclonal antibodies against NADHs9 15/22-5, Aco-I
13/18-1, GPD1 P5A1-1 and LDHA 4D3-A1 were ob-
tained (Additional file 1: Figure S1). Specific polyclonal
mouse antibodies against citrate synthase were used in
the study (Additional file 1: Figure S1) because we
failed in obtaining reliable hybridomas for this protein.
Printing and processing of reverse phase protein
microarrays
Samples from patient biopsies were diluted in PBS
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and
1.8 mM KH2PO4 pH 7.4) to a final protein concentra-
tion of 1 μg/μl before printing. Serially diluted protein
extracts (0–1 μg/μl) derived from HCT116 colocarci-
noma cells were also prepared to asses printing quality
and the linear response of protein recognition by the
antibodies used. A solution of BSA (1 μg/μl) was also
prepared for printing as internal negative control. Ap-
proximately, 1 nl volume of each sample was spotted in
quadruplicate onto nitrocellulose-coated glass slides
(FAST Slides, Schleicher & Schuell BioScience, Inc. Das-
sel, Germany) using a BioOdyssey Calligrapher MiniA-
rrayer printer (Bio-Rad Laboratories, Inc., Madrid,
Spain) equipped with a solid pin (MCP310S) at constant
humidity of 45% and 10°C and 16°C for the plate and
chamber, respectively. After printing, arrays were
allowed to dry at room temperature for 16 hours and
further blocked in PBS-T containing 5% skimmed milk.
After, the arrays were incubated overnight at 4°C with
the indicated concentrations of the following highly spe-
cific primary monoclonal antibodies (mAbs): anti-β-F1-
ATPase (1:150), anti-Hsp60 (1:150), anti-GAPDH (1:250)
and anti-PK (1:150) from [4], anti-IF1 (1:50) from [12],
anti-α-F1-ATPase (1:250), anti-COXI (1:85) and anti-COXIV (1:50) from Molecular Probes (Madrid, Spain),
anti-PDH (1:50) and anti-SDH (1:50) from Invitrogen
(Madrid, Spain), anti-SOD2 (1:100), anti-PYGM (1:200),
anti-β-actin (1:1000) from Sigma (Madrid, Spain), and
the additional home-made anti-NADHs9 (1:1000), anti-
LDH-A (1:2,500), anti-ACO1 (1:250) and anti-GPD1
(1:1000). The polyclonal mouse anti-CS (1:500) and
rabbit anti-CPT1M (1:25) from Santa Cruz (Heidelberg,
Germany) and anti-HADHA (1:1000) from Abcam
(Cambridge, UK) were also used. Each array was incu-
bated with each antibody independently. After incuba-
tion the arrays were washed with PBS-T and further
incubated with a donkey anti-mouse or donkey anti-
rabbit secondary antibody conjugated with alexa-488
(Invitrogen, Madrid, Spain). Microarrays were scanned
using a Typhoon 9410 scanner (GE Healthcare, Inc.
Madrid, Spain). The mean fluorescent intensity of the
spots was quantified using FIJI software (N.I.H., USA)
and converted into arbitrary units of expressed protein/
ng of total protein in the tissue extract using the expres-
sion obtained in the linear plot of the HCT116 cell line
as standard. The technical variance of the arrays calcu-
lated by the squared coefficient of variation (SCV
= σ*100/ |x|) was 8.6 ± 0.6.
Statistical analysis
Distribution of molecular markers was studied by using
a two-tailed Student's t test. Analysis of variance
(ANOVA) with post hoc Dunnett's test used for multiple
comparisons to the control and analysis of variation in
samples with box plot diagrams were performed using
the PASW statistics 18 software package. For the expres-
sion profiles of metabolic markers data were reformatted
by calculating the log(2) of the expression level in each
sample relative to the mean expression level in normal
samples. We used the Cluster Program from “Expression
Profiler Clustering home page” at http://ep.ebi.ac.uk/EP/
EPCLUST using the Euclidean distances and average
linkage method (Weighted Group Average, WPGMA).
The results shown are means ± S.E.M. A p < 0.05 was
considered statistically significant.
Results
Validation of the antibodies used for RPMA
High affinity and specific monoclonal antibodies against
proteins of energy metabolism are the rate-limiting tools
required for the successful application of RPMA tech-
nology [14]. The metabolic pathways interrogated in this
study included the degradation of glycogen (PYGM), gly-
colysis (GAPDH, PK, LDHA), the shuttling of cytosolic
electrons to mitochondria (GPD1), mitochondrial de-
carboxylation of pyruvate (PDH), the mitochondrial im-
port and oxidation of fatty acids (CPT1, HADHA), the
Krebs cycle (CS), the electron transport chain (NADHs9,
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phosphorylation (αF1, βF1, IF1), cytosolic (ACO1) and
mitochondrial (SOD2) markers of oxidative stress. In
addition, cellular (β-actin) and mitochondrial (Hsp60)
structural markers were included to normalize changes
in protein expression. The selection of target proteins
was mostly based on the facts that they are abundant
proteins in core pathways of energy provision. Hence, a
first step of this study was to validate the specificity of
the antibodies to be used in RPMA by western blotting
using human muscle extracts (Figure 1). Both the anti-
bodies commercially available or made in the lab were
tested [11,12] (and see Additional file 1: Figure S1). The
antibodies used in this study recognized one single pro-
tein band of the expected molecular weight in human
muscle samples (Figure 1), validating their utilization for



































































































Figure 1 Validation of the antibodies used for application in RPMA. 3
on SDS-PAGE gels (see Coomasie blue stained track on top-left), blotted ag
antibodies that recognize a single protein band of the expected molecular
is indicated to the left.Protein expression in human muscle biopsies
A representative protein microarray illustrating the
printing protocol of human muscle biopsies developed
with antibodies against the glycolytic LDH-A is shown
in Figure 2A. Arrays developed with other antibodies are
shown below (Figure 2A). Protein extracts from muscle
biopsies of control (green boxed in Figure 2A) and dif-
ferent neuromuscular diseases (red boxed in Figure 2A)
were prepared and spotted onto RPMA in quadruplicate
from left to right (Figure 2A). Increasing amounts of
BSA (black boxed in Figure 2A) were spotted in the
array as a control of the background of the assay. The
arrays also contained increasing protein amounts of cel-
lular extracts derived from HCT116 cells (blue boxed in
Figure 2A). The HCT116 extracts revealed a linear in-
crease in fluorescent intensity as the amount of protein
increased in the spot (Figure 2B), providing the standard





















































































0–40 μg of protein derived from human muscle (M) were fractionated
ainst the indicated antibodies and processed for western blotting. Only
mass were used in the study. The migration of molecular mass markers
AB
Figure 2 Printing of RPMA. A, Scheme of RPMA printing processed for anti-LDH-A is shown magnified. One nl samples were spotted in quadruplicate.
Black boxed: negative controls of BSA; Blue boxed: standard curves of HCT116 cells; Green boxed: tissue samples from control donors; Red boxed: tissue
samples from patients. Below are shown representative RPMAs processed with other antibodies. B, The plot illustrates the linear correlation that exists
between the fluorescence intensity (arbitrary units, a.u.) and the amount of LDH-A protein in HCT116 cell lysates. Protein concentrations in the biopsies
were calculated according to the fluorescence intensity obtained in the linear plot of HCT116 cells. For other details see Additional file 2: Figure S2.
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responding antigen in minute amounts of printed pro-
tein of HCT116 extracts as well as in the biopsies
(Figure 2A). As expected, no fluorescent signal was
observed in BSA containing spots (Figure 2A), which
provides the background of the technique by non-
specific absorption of labeled antibodies to the proteins
spotted. The quantification of the expression of each
marker in control (n =20) and patient (n =53) biopsies
was calculated by interpolating the fluorescent intensity
signal obtained in the sample in the linear plot of
HCT116 cells (Figure 2A and Additional file 2: Figure S2)
and expressed as fold of control. Array duplicates showTable 1 Relative expression of proteins of energy metabolism
Rare Diseases
Metabolic Muscular Dy
Controls Mitochondrial Glycogenosis DMD BM
Complex I type V
Mitochondrial
Markers
PDH E1α 1.0 ± 0.1 1.3 ± 0.1 0.6 ± 0.1 1.3 ± 0.2 1.3
SDH 1.0 ± 0.1 1.4 ± 0.1 ** 0.9 ± 0.1 1.4 ± 0.2 * 1.1
CS 1.0 ± 0.1 1.5 ± 0.2 * 0.8 ± 0.1 1.1 ± 0.3 0.8
Hsp60 1.0 ± 0.1 1.3 ± 0.1 0.8 ± 0.1 1.7 ± 0.2 ** 1.2
CPT1-M 1.0 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 1.2 ± 0.2 0.7
HADHA 1.0 ± 0.1 1.6 ± 0.2 * 1.1 ± 0.2 0.7 ± 0.1 0.7
NADH-9 1.0 ± 0.1 1.8 ± 0.2 ** 1.2 ± 0.1 0.9 ± 0.1 0.9
COX-1 1.0 ± 0.1 1.2 ± 0.1 0.6 ± 0.1 * 1.5 ± 0.1 * 1.3
α-F1 1.0 ± 0.1 1.1 ± 0.1 0.7 ± 0.2 1.4 ± 0.1 * 1.3
β-F1 1.0 ± 0.1 1.3 ± 0.1 * 0.9 ± 0.1 1.2 ± 0.2 1.2
IF1 1.0 ± 0.1 1.0 ± 0.1 0.7 ± 0.1 1.1 ± 0.2 1.1
SOD2 1.0 ± 0.1 0.8 ± 0.1 1.0 ± 0.1 0.5 ± 0.1 * 0.5
Cytoplasmic
Markers
β-Actin 1.0 ± 0.1 1.1 ± 0.1 1.3 ± 0.2 1.0 ± 0.1 1.1
GAPDH 1.0 ± 0.1 0.6 ± 0.1 * 0.8 ± 0.1 0.4 ± 0.1 * 0.9
PK 1.0 ± 0.1 1.0 ± 0.1 0.8 ± 0.1 0.8 ± 0.2 1.0
LDH-A 1.0 ± 0.1 0.7 ± 0.1 0.6 ± 0.2 0.4 ± 0.1 * 0.6
GPD1 1.0 ± 0.1 1.1 ± 0.1 0.9 ± 0.1 0.4 ± 0.1 ** 0.7
PYGM 1.0 ± 0.1 1.5 ± 0.2 * 0.0 ± 0.0 ** 0.2 ± 0.1 ** 0.7
ACO1 1.0 ± 0.1 1.1 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 1.1
Ratios
β-F1/GAPDH 1.0 ± 0.1 2.5 ± 0.3 ** 1.1 ± 0.2 3.1 ± 0.8 ** 2.2
BEC Index 1.0 ± 0.1 2.1 ± 0.2 ** 1.4 ± 0.2 1.6 ± 0.3 * 1.8
β-F1/LDH-A 1.0 ± 0.1 2.2 ± 0.3 ** 1.8 ± 0.5 * 3.5 ± 0.6 ** 2.7
The table summarizes the expression of nineteen proteins involved in different mit
from them in different muscle myopathies when compared to controls. Values are
*, p < 0.05 and **, p < 0.001 when compared to controls.that the results obtained are highly reproducible validating
the robustness of the technique for quantitative purposes
(see Additional file 3: Figure S3).
The analysis of protein expression comparing patient’s
samples to their respective controls taking into consider-
ation the muscle type of origin (deltoid or quadriceps;
see printing scheme of the arrays on Figure 2) provided
no significant differences. Hence, and for the sake of
simplicity, we decided to present the data of controls all
together (Table 1). The results in Table 1 and Additional
file 4: Figure S4 summarizes the expression of nineteen
proteins involved in different cellular activities and of




D C. Xp21 LGMD 2C NCL ICU
± 0.4 0.7 ± 0.1 0.8 ± 0.1 0.7 ± 0.1 0.6 ± 0.1
± 0.2 0.9 ± 0.2 0.6 ± 0.1 * 1.0 ± 0.2 0.8 ± 0.1
± 0.1 1.4 ± 0.4 0.5 ± 0.2 1.1 ± 0.3 1.2 ± 0.1
± 0.2 0.9 ± 0.2 1.3 ± 0.3 0.9 ± 0.2 0.8 ± 0.1
± 0.0 * 0.9 ± 0.0 0.7 ± 0.2 1.0 ± 0.1 1.0 ± 0.1
± 0.1 0.8 ± 0.2 0.8 ± 0.3 1.1 ± 0.2 1.4 ± 0.2
± 0.2 1.0 ± 0.2 0.6 ± 0.2 1.0 ± 0.1 1.2 ± 0.2
± 0.3 0.9 ± 0.1 0.9 ± 0.2 0.8 ± 0.1 0.7 ± 0.1
± 0.5 0.8 ± 0.1 1.0 ± 0.2 1.1 ± 0.2 0.7 ± 0.1
± 0.1 1.2 ± 0.3 0.8 ± 0.1 0.8 ± 0.1 1.0 ± 0.1
± 0.2 0.7 ± 0.1 0.8 ± 0.2 0.7 ± 0.1 * 0.6 ± 0.1 *
± 0.1 * 0.7 ± 0.2 0.8 ± 0.3 0.8 ± 0.1 1.0 ± 0.1
± 0.3 1.0 ± 0.1 0.8 ± 0.2 1.1 ± 0.1 1.2 ± 0.2
± 0.3 0.6 ± 0.1 0.3 ± 0.1 * 0.6 ± 0.1 0.5 ± 0.1 *
± 0.2 0.8 ± 0.0 0.7 ± 0.1 0.6 ± 0.1 * 0.7 ± 0.1 *
± 0.2 0.5 ± 0.0 0.3 ± 0.0 * 0.4 ± 0.1 * 0.4 ± 0.1 *
± 0.2 0.6 ± 0.1 * 0.6 ± 0.2 * 0.5 ± 0.1 * 0.7 ± 0.1
± 0.3 0.7 ± 0.1 0.5 ± 0.1 * 0.5 ± 0.1 * 0.4 ± 0.1 **
± 0.3 0.9 ± 0.2 0.7 ± 0.2 1.0 ± 0.1 0.7 ± 0.1
± 1.0 * 1.6 ± 0.4 2.9 ± 0.6 ** 1.3 ± 0.3 1.7 ± 0.3 *
± 0.5 * 1.9 ± 0.2 * 2.5 ± 0.5 ** 1.9 ± 0.5 * 2.5 ± 0.5 **
± 0.8 ** 1.9 ± 0.4 * 2.5 ± 0.5 ** 1.8 ± 0.3 ** 3.2 ± 0.7 **
ochondrial and cytoplasmic activities of metabolism and of the ratios derived
expressed as fold of control. The results shown are the mean values ± S.E.M.
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file 4: Figure S4 illustrate the individual variation of the
expression of the markers in each group of the pathologies
studied as well as the outliers. In general, only Complex I
deficient patients and patients affected of Duchenne mus-
cular dystrophy showed a significant increase in several
mitochondrial markers involved in energy metabolism
when compared to controls (Table 1 and Additional file 4:
Figure S4). Paradoxically, NADH-dehydrogenase subunit
9 expression was significantly increased in Complex I defi-
cient patients (Table 1 and Additional file 4: Figure S4). A
significant reduction in SOD2 expression was also noted
in Duchenne and Becker muscular dystrophies (Table 1
and Additional file 4: Figure S4). Similarly, expression of
the inhibitor of the mitochondrial H+-ATP synthase, IF1,
was also significantly diminished in patients affected of
intense care unit and NCL myopathies (Table 1 and
Additional file 4: Figure S4). This finding is consistent
with the recent observation that inhibition of IF1 amelio-
rates severe mitochondrial respiratory chain dysfunctions
[15]. In general, mitochondrial markers showed slight varia-
tions when compared to controls in glycogenosis type V,
Becker and symptomatic forms of DMD and BMD in
female carrier muscular dystrophies, patients affected
of intensive care unit myopathy and NCL (Table 1 and
Additional file 4: Figure S4).
However, Complex I deficient patients and patients
affected of Duchenne Muscular Dystrophy, Limb Girdle
Muscular Dystrophy Type 2C (LGMD2C), Neuronal
Ceroid Lipofuscinosis and patients affected of intensive
care unit myopathy provided significant differences in
the expression of several of the cytosolic biomarkers
studied when compared to control donors (Table 1 and
Additional file 4: Figure S4). A significant decrease in
the expression of myophosphorylase and several of the
glycolytic enzymes was observed in muscular dystrophies
(Duchenne Muscular Dystrophy, Limb Girdle Muscular
Dystrophy Type 2C (LGMD2C), Neuronal Ceroid
Lipofuscinosis and patients affected of intensive care
unit myopathy) (Table 1 and Additional file 4: Figure S4).
Remarkably, whereas myophosphorylase expression was
increased in Complex I deficient biopsies (Table 1 and
Additional file 4: Figure S4) it was completely vanished in
patients affected of Glycogenosis type V (Table 1 and
Additional file 4: Figure S4), consistent with the lack of
myophosphorylase activity in McArdle disease [16,17].
Based on the opposite expression that exists between
glycolytic and bioenergetic markers of the mitochon-
dria during development, differentiation and in cancer
[18], we calculated the bioenergetic signature of the
biopsies (BEC index = βF1/Hsp60/GAPDH ratio) [3]
and different alternative ratios between the catalytic subunit
of the H+-ATP synthase (β-F1-ATPase) and the expression
of GAPDH or LDH-A (Table 1 and Additional file 4:Figure S4) [19]. Remarkably, the normalized cellular
content of β-F1-ATPase, as assessed by the β-F1/LDH-
A ratio, was significantly augmented in all the diseases
studied despite the expression of the two markers alone
showed no major differences. These findings supported
the β-F1-ATPase/LDH-A ratio as a bioenergetic signa-
ture of muscular affectation independent of the differ-
ent genetic or epigenetics mechanisms involved in the
onset of neuromuscular diseases (Table 1).
Enzymes of metabolism as biomarkers of rare diseases
Having observed significant differences in the expression
of proteins of energy metabolism for a diverse set of rare
neuromuscular diseases, we next questioned their poten-
tial as discriminatory biomarkers of disease. To this aim,
we carried out unsupervised hierarchical clustering of
the biopsies using the expression of 4–5 markers for
aggregation purposes. This statistical method groups
samples by similarity of expression in different groups or
clusters [20]. To illustrate this point, the clustering of
the 39 biopsies of control, deficit of Complex I activity
and of the expression of myophosphorylase using the ex-
pression of NADH dehydrogenase subunit 9, myopho-
sphorylase and the β-F1-ATPase/GAPDH ratio resulted
in the distribution of the biopsies in three separate
groups with a classification sensitivity of 95% and 100%
for complex I and myophosphorylase deficiencies, re-
spectively (Figure 3A). A classification specificity of 90%
and 100% for controls was also observed (Figure 3A).
Hierarchical clustering of 42 biopsies of control and the
four muscular dystrophies studied (DMD, BMD, Xp21
and LGMD2C) using the expression of LDH-A, the BEC
index and PYGM resulted in two clearly distinguished
groups corresponding to controls and dystrophic pa-
tients with a classification sensitivity of 96% for the
pathologic samples and a specificity of 83% for the con-
trols (Figure 3B). The same type of analysis using 26 bi-
opsies of control and patients affected of NCL according
to the expression pattern of PYGM, GPD1 and β-F1/
LDH-A ratio resulted in their distribution into two dif-
ferent groups, control donors and NCL patients, with a
high sensitivity (100%) and specificity (85%) (Figure 3C).
Inter-individual variation of the expression of the
biomarkers (Additional file 4: Figure S4) is usually a
handicap for its translation because they not always
qualify for clinical use. Table 2 provides a summary of
the power to discriminate different neuromuscular
dystrophies/myopathies by the combination of the
value of the β-F1-ATPase/LDH-A ratio with the ex-
pression level of a third biomarker. It should be noted
that these combinations have 100% sensitivity (Table 2)
when the markers used have no outliers (Additional







Figure 3 Hierarchical clustering analyses of the biopsies using enzymes of energy metabolism. Rows indicate type of sample, columns,
proteins and derived ratios. Protein expression scores are shown normalized to the mean relative expression level in normal samples, according to a
color scale (below panels): red indicates high; black, normal; and green, low expression. The dendogram (to the right of the matrix) represents overall
similarities in expression profiles. The maximum and minimum values of the markers for each cluster are shown. A, Clustering of normal (CTR), isolated
deficit of Complex I activity (MITO) and myophosphorylase (GlycV) biopsies using β-F1-ATPase/GAPDH ratio, PYGM and NADHs9 as biomarkers.
B, Clustering of normal (CTR) and DMD, BMD, Xp21 and LGMD2C muscular dystrophies using LDH-A, BEC index and PYGM as biomarkers. C,
Clustering of normal (CTR) and Neuronal Ceroid Lipofuscinosis (NCL) biopsies using PYGM, GPD1 and β-F1-ATPase/LDHA ratio as biomarkers.
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A large number of genes have been identified to be in-
volved in different muscle-wasting neuromuscular disor-
ders. However, knowledge of the pathophysiological
mechanisms, markers of diagnosis and treatment of rare
muscular diseases is scant or non-existent. Over the last
two decades, remarkable progress has been made in the
development of genetic-targeted therapeutic interven-
tions for several muscular dystrophies [21]. More re-
cently, next-generation sequencing (NGS) technologies
have also been implemented for the identification of the
genetic causes underlying neuromuscular diseases
[22,23]. Much less studies have dealt with the analysis of
the proteome of neuromuscular diseases despite having
been demonstrated that the alterations in the expression
of proteins of energy metabolism provides useful bio-
markers in a complex genetic disorder such as cancer
[5,6,19,24]. Within this context, RPMA offers a high-Table 2 Potential diagnostic sensitivity of some
metabolic biomarkers in neuromuscular dystrophies/
myopathies
Disease β-F1/LDH-A AdditionalMarkers Sensitivity
DMD (2.9-4.1) PYGM (0.1-0.3) 100%
BMD (1.9-3.5) GAPDH (0.6-1.2) 86%
NCL (1.5-2.1) GPD1 (0.4-0.6) 100%
LGMD-2C (2.5-3.9) SDH (0.5-0.7) 100%
The table summarizes the power to discriminate (sensitivity) the neuromuscular
dystrophies/myopathies by the combination of the value of the β-F1-ATPase/
LDH-A ratio with the expression level of a third biomarker. Sensitivity was
calculated according to the classification rate of true positive samples following
the formula: Sensitivity = True positives/(True positives + False positives).throughput technology for quantitative determination of
the proteins that define the particular phenotype of a
disease. RPMA allows the interrogation and identifica-
tion of potential biomarkers, the establishment of corre-
lations with patients’ outcome [4] and eventually, the
design of future rationale therapeutic approaches based
on the biomarkers identified [7,24]. In this study we have
developed five additional highly specific monoclonal
antibodies against proteins of energy metabolism and in-
terrogated a cohort of muscle biopsies of patients af-
fected of neuromuscular diseases by applying the RPMA
technology using nineteen different antibodies. The pur-
pose was the identification of proteins that could inform
of the activity of energy metabolism and could provide
potential biomarkers for these diseases as an additional
effort to stimulate its translation to bed-side application
in this orphan field of investigation. Although we have
not taken into account the age of patients [25], the spe-
cific type of muscle fibers and/or the presence of nec-
rotic areas in the biopsies, which are known factors that
influence protein expression [26,27], the low dispersion
of the values obtained for each marker suggests that
these are not main factors contributing to the differences
reported.
Muscular dystrophies are a heterogeneous group of
inherited disorders characterized by progressive muscle
wasting and weakness [21,28,29]. Previous studies have
suggested the potential relevance of the metabolic en-
zymes enolase and malate dehydrogenase as biomarkers
of these disorders in animal models [30]. In this regard,
we have extended the list of potential metabolic
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with findings in dystrophic dog muscle [30], we can con-
firm the down-regulation of the expression of most
glycolytic proteins in human dystrophic muscle. In con-
trast to the findings in dystrophic dog muscle [30], we
observed the up-regulation of mitochondrial proteins in-
volved in oxidative phosphorylation in human dystrophic
muscle. The analysis of mitochondrial function in a
cardiotoxin-induced mouse model of muscular dys-
trophy [29] has revealed an impaired expression of mito-
chondrial proteins involved in the respiratory chain and
oxidative phosphorylation (OXPHOS). These results con-
trast our findings in which it is observed, if any, a signifi-
cant increase in several markers of the respiratory chain
and OXPHOS (Table 1 and Additional file 4: Figure S4).
These discrepancies might arise from differences between
human and mouse muscle and/or from the experimental
system and approaches used in these studies.
The most common and severely debilitating neuro-
muscular disorder, Duchenne muscular dystrophy, af-
fects ~1 in 3,500 males and it is manifested by rapidly
progressive proximal muscle wasting, respiratory insuffi-
ciency and cardiac failure that lead to premature death
by the mid-20s [28]. The allelic disorder Becker muscu-
lar dystrophy is less common and milder, with relatively
advanced survival age. Consistent with this, we have ob-
served a lesser alteration of the expression of proteins of
energy metabolism in biopsies of BMD patients (Table 1
and Additional file 4: Figure S4). Both diseases are
caused by mutations in the dystrophin gene, one of the
largest gene in the human genome, located on the X
chromosome encoding a 427kD protein [28,31]. Dys-
trophin interacts with multiple proteins to assemble the
dystrophin-associated protein complex (DAPC), a group
of proteins that span the sarcolemma of the skeletal and
cardiac muscle [21]. The core component of the DAPC
is dystroglycan whose insufficient post-translational gly-
cosylation is responsible for sarcoglycanopathies, a clin-
ically heterogeneous group of congenital muscular
dystrophies [28]. Within the DAPC, the subcomplex of
integral proteins sarcoglycans and sarcospan provides
additional mechanical support to the sarcolemma [32].
Mutations in genes encoding α, β, γ and δ subunits of
the sarcoglycan complex cause sarcoglycanopathies, a
subtype of recessively inherited limb-girdle muscular
dystrophies (LGMDs) that also express a significant
down-regulation of four cytoplasmic markers of energy
metabolism, partially mimicking the findings observed in
DMD (Table 1 and Additional file 4: Figure S4).
Different molecular mechanisms are responsible for
the muscle wasting phenotypes [33]. However, it is note-
worthy that the bioenergetic signature, as assessed by
the β-F1-ATPase/LDH-A ratio, is always affected regard-
less of the muscular disease studied. The mechanismspromoting the global alteration of energy metabolism in
the muscle of patients affected with a neuromuscular
disease, best exemplified by the dramatic increase in the
β-F1-ATPase/LDH-A ratio (Table 1), has remained
largely unexplained. Perhaps, because it stems from the
idea that only global gene expression analysis could be
useful to delineate the pathophysiology of the disease.
However, the situation is that genetic alterations that re-
sult in neuromuscular dystrophies vary from one specific
disease to another but apparently act pleiotropically to
regulate, either by genetic or epigenetic means (ICU
patients), the signature of muscle energy metabolism.
Moreover, the quantification of the β-F1-ATPase/
LDH-A ratio in addition to other proteins of energy me-
tabolism provides a valuable fingerprint to discriminate
between different myopathies (Table 2). Interestingly,
the combination of the β-F1-ATPase/LDH-A ratio with
the expression of myophosphorylase (PYGM) allows the
discrimination of DMD patients with 100% of sensitivity
(Table 2). Similarly, combination of this ratio with GPD1
expression discriminates patients affected of NCL with a
classification sensitivity of 100% (Table 2). Moreover, the
GAPDH and succinate dehydrogenase (SDH) in combin-
ation with the β-F1-ATPase/LDH-A ratio discriminate
BMD (86% sensitivity) and LGMD-2C (100% sensitivity)
diseases, respectively (Table 2). The metabolic markers
that we have uncovered, alone or in combination with
the detection of serum biomarkers [25,34,35] and/or
other markers of energy metabolism that have been pre-
viously linked to muscular dystrophy in mdx models
[30] and patients [35] could aid therapeutic clinical man-
agement of patients affected of these disorders.
Conclusions
Our study addresses the challenge of utilizing markers of
energy metabolism to be used for translation in aiding the
management of rare neuromuscular diseases patients. We
demonstrate that the quantification of proteins of energy
metabolism in a cohort of seventy three muscle biopsies
of control donors and patients affected of different neuro-
muscular diseases offers sensitive and specific biomarkers
that could be implemented to refine the understanding of
the biological principles of rare diseases and, eventually,
the management of these patients.
Additional files
Additional file 1: Figure S1. Characterization of the antibodies
produced. Representative Western blot analysis showing the reactivity of
the different antibodies produced against recombinant proteins and
native proteins in different human cell lines (HCT116, HepG2 and 293 T)
and human liver. The antibodies (0.4 μg/ml) exclusively recognized the
recombinant (R; 50–100 ng of protein) and native protein (truncated
Aconitase I, AcoI; Citrate synthase, CS; glycerol-3-phosphate dehydrogenase
1, GPD1; lactate dehydrogenase A, LDH-A and NADH-ubiquinone
Santacatterina et al. Journal of Translational Medicine  (2015) 13:65 Page 10 of 11oxidoreductase α-sub9, NADH-sub9). Note the lower electrophoretic
mobility of the recombinant protein in most cases due to the tag used
for purification.
Additional file 2: Figure S2. Linear correlation between the
fluorescence intensity and the content of protein in HCT116 cells. Cell
extracts (0–1 μg/μl) were spotted in the arrays (see Figure 2A). Significant
linear correlations were obtained between the fluorescence intensity
(arbitrary units, a.u) of the spots and the amount the protein interrogated
in the arrays. Protein concentrations in the biopsies were calculated by
interpolation in the respective linear plots.
Additional file 3: Figure S3. Validation of RPMA reproducibility.
Histograms represent two different experiments (grey and red bars) of
RPMA for GAPDH in different neuromuscular dystrophies/myopathies
when compared to control donors, confirming that the results obtained
with the RPMA approach are highly reproducible.
Additional file 4: Figure S4. Quantitative analysis of the expression of
proteins of metabolism represented as box plots. The Y axis indicates the
values of intensity (a.u) calculated by interpolation in the linear plot of
HCT116 cells and normalized by the expression values of β-actin. The X
axis represents patient groups. Box plots represent the lowest, lower
quartile, median, upper quartile, and highest observations of each marker
in the different groups of pathologies. ○, outlier values and #, extreme
values. * and **, p < 0.05 and p < 0.001 when compared to controls,
respectively.
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